SIX Financial Information

Enter Ticker Symbol:

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for PURE Bioscience (PURE : OTC)

• Company Description

PURE Bioscience develops and markets technology-based bioscience products that provide solutions to numerous global health challenges, including methicillin-resistant Staphylococcus aureus (MRSA), or staph infection. PURE's proprietary high efficacy/low toxicity bioscience technologies, including its silver dihydrogen citrate-based antimicrobials, represent innovative advances in diverse markets and lead today's global trend toward industry and consumer use of `green` products while providing competitive advantages in efficacy and safety. Patented SDC is an electrolytically generated source of stabilized ionic silver which formulates well with other compounds. As a platform technology, SDC is distinguished from competitors in the marketplace because of its superior efficacy, reduced toxicity and the inability of bacteria to form a resistance to it.
Number of Employees: 12

• Price / Volume Information

Yesterday's Closing Price: $0.08 Daily Weekly Monthly

20 Day Moving Average: 43,715 shares

Shares Outstanding: 111.89 (millions)

Market Capitalization: $9.10 (millions)

Beta: 0.52

52 Week High: $0.14

52 Week Low: $0.04

Short Interest Ratio:

% Price Change % Price Change Relative to S&P 500

4 Week 45.18% 50.80%

12 Week 75.59% 83.74%

Year To Date 93.57% 100.02%

• Address & Contact Information

Street Address Phone / Fax Email Address Web URL

771 JAMACHA ROAD #512
-
EL CAJON,CA 92019
USA ph: 619-596-8600
fax: 619-596-8790 melliott@purebio.com http://www.purebio.com

• General Corporate Information

Officers

Robert Bartlett - President; Chief Executive Officer
Ivan Chen - Chairman of the Board
Mark Elliott - Vice President; Finance;Principal Financial and Ac
Tom Myers - Director
David Rendall - Director

Peer Information

PURE Bioscience (BJCT)
PURE Bioscience (CADMQ)
PURE Bioscience (APNO)
PURE Bioscience (UPDC)
PURE Bioscience (IMTIQ)
PURE Bioscience (CYGN)

Industry / Sector / Ticker Info

Analyst Coverage: No
Industry Group: MED PRODUCTS
Sector: Medical
CUSIP: 74621T209
SIC: 2890

Fiscal Year

Fiscal Year End: July
Last Reported Quarter: 01/01/26
Next Expected EPS Date: 06/15/26

Share - Related Items

Shares Outstanding: 111.89
Most Recent Split Date: 8.00 (0.13:1)
Beta: 0.52
Market Capitalization: $9.10 (millions)

• EPS Information    • Dividend Information

Analyst Coverage: No Dividend Yield: 0.00%

Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00

Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio:

Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio:

Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00

Next EPS Report Date: 06/15/26

• Fundamental Ratios

P/E

Current FY Estimate: -
Trailing 12 Months: -
PEG Ratio: -

Price Ratios

Price/Book: -
Price/Cash Flow: -
Price / Sales: 2.71

EPS Growth

vs. Year Ago Period: 0.00%
vs. Previous Quarter: -%

Sales Growth

vs. Year Ago Period: 13.55%
vs. Previous Quarter: -37.29%

ROE

01/31/26 - -
10/31/25 - -
07/31/25 - -

ROA

01/31/26 - -356.86
10/31/25 - -377.91
07/31/25 - -430.22

Current Ratio

01/31/26 - 0.25
10/31/25 - 0.37
07/31/25 - 1.12

Quick Ratio

01/31/26 - -
10/31/25 - 0.30
07/31/25 - 0.97

Operating Margin

01/31/26 - -108.77
10/31/25 - -110.91
07/31/25 - -123.44

Net Margin

01/31/26 - -108.77
10/31/25 - -110.91
07/31/25 - -123.44

Pre-Tax Margin

01/31/26 - -64.43
10/31/25 - -65.86
07/31/25 - -108.95

Book Value

01/31/26 - -0.06
10/31/25 - -0.05
07/31/25 - -0.05

Inventory Turnover

01/31/26 - 5.14
10/31/25 - 6.34
07/31/25 - 8.58

Debt-to-Equity

01/31/26 - -
10/31/25 - -
07/31/25 - -

Debt-to-Capital

01/31/26 - -
10/31/25 - -
07/31/25 - -

Powered by Zacks Investment Research ©